![MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/6f4d6f2e2159220a3406f67f0e6f82f9.jpg "MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]")
MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]
Update: 2022-02-06
Description
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit
Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel,
discuss several important presentations from the recent 2021 ASH meeting.
They focus on the new IPSS-M classification, discuss the approach to the
MDS patient who is currently defined by IPSS/R as belonging to the /lower-
risk group but in fact the disease behaves like a higher-risk. Finally, they
discuss issues regarding the treatment of patients with HR-MDS: What can be
added to hypomethylating agents ? Targeted therapy with IDH1/2 inhibition
and more…
Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel,
discuss several important presentations from the recent 2021 ASH meeting.
They focus on the new IPSS-M classification, discuss the approach to the
MDS patient who is currently defined by IPSS/R as belonging to the /lower-
risk group but in fact the disease behaves like a higher-risk. Finally, they
discuss issues regarding the treatment of patients with HR-MDS: What can be
added to hypomethylating agents ? Targeted therapy with IDH1/2 inhibition
and more…
Comments
In Channel
![Pathogenesis and inflammaging in MDS [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/c8c843cc8c8e08a4761e7c633e0046c2.jpg "Pathogenesis and inflammaging in MDS [MDS Professional Report]")
![Treatment of lower-risk MDS [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/59731ffad6896313dd70ce957e619b02.jpg "Treatment of lower-risk MDS [MDS Professional Report]")
![Treatment for Higher-risk MDS [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/474af5f93a7c919181979937a2ea20a4.jpg "Treatment for Higher-risk MDS [MDS Professional Report]")
![Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/6fb86eb9669a4d2de76fbe628d3c3231.jpg "Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report]")
![Transfusions and quality of life [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/7b8bc7d62bbbfefa1a0c2f97a3d163fe.jpg "Transfusions and quality of life [MDS Professional Report]")
Download from Google Play
Download from App Store
United States00:00
00:00
x
